Education
About Us
Working with TipRanks
Follow Us
Meiragtx Holdings Plc (MGTX)
NASDAQ:MGTX
MGTX Stock Chart & Stats
$8.04
-$0.03(-0.47%)
At close: 4:00 PM EST
$8.04
-$0.03(-0.47%)
Day’s Range― - ―
52-Week Range$4.55 - $9.73
Previous CloseN/A
Volume124.17K
Average Volume (3M)365.46K
Market Cap
$630.24M
Enterprise Value$699.44M
Total Cash (Recent Filing)$14.84M
Total Debt (Recent Filing)$88.06M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 12, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding80,490,890
10 Day Avg. Volume401,028
30 Day Avg. Volume365,461
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)6.27
Price to Sales (P/S)12.78
P/FCF Ratio-3.89
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue25.51
Enterprise Value/Gross Profit62.21
Enterprise Value/Ebitda-4.87
Forecast
1Y Price Target
$20.00Price Target Upside148.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic CollaborationThe collaboration with Eli Lilly provides a $75 million upfront payment and potential milestone payments, enhancing MeiraGTx's revenue streams and solidifying its leadership in genetic medicine.
Revenue GrowthA substantial revenue growth rate indicates strong market demand for MeiraGTx's gene therapy products, supporting long-term business expansion and sustainability.
Market PositionSuccess in the AAV-AIPL1 program for vision restoration highlights MeiraGTx's innovative edge and strengthens its competitive position in the gene therapy market.
Bears Say
Financial InstabilityThe negative equity and high leverage indicate financial instability, which can hinder MeiraGTx's ability to invest in R&D and limit operational flexibility.
Profitability ChallengesPersistent negative profit margins reflect ongoing struggles to achieve profitability, necessitating significant improvements in cost management and revenue generation.
Cash Flow DifficultiesNegative cash flows highlight challenges in generating sufficient cash to support operations, increasing reliance on external financing and impacting long-term viability.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings Plc’s price range in the past 12 months?
Meiragtx Holdings Plc lowest stock price was $4.55 and its highest was $9.73 in the past 12 months.
What is Meiragtx Holdings Plc’s market cap?
Meiragtx Holdings Plc’s market cap is $630.24M.
When is Meiragtx Holdings Plc’s upcoming earnings report date?
Meiragtx Holdings Plc’s upcoming earnings report date is Mar 12, 2026 which is in 35 days.
How were Meiragtx Holdings Plc’s earnings last quarter?
Meiragtx Holdings Plc released its earnings results on Nov 13, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.49 by -$0.13.
Is Meiragtx Holdings Plc overvalued?
According to Wall Street analysts Meiragtx Holdings Plc’s price is currently Undervalued.
Does Meiragtx Holdings Plc pay dividends?
Meiragtx Holdings Plc does not currently pay dividends.
What is Meiragtx Holdings Plc’s EPS estimate?
Meiragtx Holdings Plc’s EPS estimate is -0.57.
How many shares outstanding does Meiragtx Holdings Plc have?
Meiragtx Holdings Plc has 80,490,890 shares outstanding.
What happened to Meiragtx Holdings Plc’s price movement after its last earnings report?
Meiragtx Holdings Plc reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.49. Following the earnings report the stock price went down -4.619%.
Which hedge fund is a major shareholder of Meiragtx Holdings Plc?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (148.76% Upside)
$20.00 (148.76% Upside)
Blogger Sentiment
Bullish
MGTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 97.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 6.9%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.15%
12-Months-Change
Fundamentals
Return on Equity
-611.42%
Trailing 12-Months
Asset Growth
-36.73%
Trailing 12-Months
Company Description
Meiragtx Holdings Plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$20.00
▲(148.76% Upside)
Technical Analysis
Ownership Overview
16.81% Insiders
1.96% Mutual Funds
0.49% Other Institutional Investors
77.10% Public Companies and
Individual Investors